SCHEDULE: AQR Capital Management Discloses 5.09% Stake in Exelixis

AQR Capital Management, LLC and its parent company have reported a 5.09% beneficial ownership stake in Exelixis, Inc., totaling 13,658,388 shares, held in the ordinary course of business.

Summary

• AQR Capital Management, LLC and AQR Capital Management Holdings, LLC collectively reported beneficial ownership of 13,658,388 shares of Exelixis, Inc. common stock.
• This ownership represents 5.09% of the class of securities.
• The shares are held with shared voting power and shared dispositive power by both AQR Capital Management, LLC and AQR Capital Management Holdings, LLC.
• The acquisition of these securities was in the ordinary course of business and not for the purpose of changing or influencing control of Exelixis, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, typical for a routine disclosure of beneficial ownership by an institutional investor, indicating neither overwhelmingly positive nor negative sentiment.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership positions, which can signal institutional confidence or portfolio rebalancing within the biotechnology sector. Exelixis operates in a competitive pharmaceutical landscape, and AQR's stake indicates its inclusion in their investment strategies.

Key Dates

Keywords

Exelixis, AQR Capital Management, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals